Discover

BEAM
Beam Therapeutics Inc.
33.48
1 x 25.75
2 x 42.26
bid
ask
-
0.84
2.45%
2 @ 07:14 AM
32.98 -0.50 (1.51%)
Ytd20.78%
1y90.99%
32.84
day range
35.81
15.60
52 week range
36.88
Open34.41Prev Close34.32Low32.84High35.81Mkt Cap3.44B
Vol2.14MAvg Vol2.18MEPS-0.49P/EN/AForward P/E-7.06
Beta2.20Short Ratio14.62Inst. Own107.03%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0450-d Avg30.89200-d Avg27.561yr Est51.07

BEAM News

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)
benzinga.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
benzinga.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

benzinga.com
The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For Phenylketonu

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines

benzinga.com
Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 An

BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical

benzinga.com
Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

benzinga.com
Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analys

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
benzinga.com
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday
benzinga.com
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

benzinga.com
Beam Therapeutics Publishes BEACON Phase 1/2 Data For Risto-Cel In Patients With Sickle Cell Disease

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Tre

benzinga.com
Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68

Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and rais

Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
benzinga.com
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels

Beam Therapeutics shares rise after BEAM-302 trial data show sustained AAT levels above threshold, s

benzinga.com
Beam Therapeutics Announces Updated Safety And Efficacy Data From Ongoing Phase 1/2 Trial Of BEAM-30

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patient

benzinga.com
Beam Therapeutics Terminates Bio Palette License Agreement, Activates Direct Patent License From Kob

Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kob

benzinga.com
RBC Capital Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $26

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and

benzinga.com
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $65

Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform an

What's Going On With Beam Therapeutics Stock?
benzinga.com
What's Going On With Beam Therapeutics Stock?

Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly resu

benzinga.com
Beam Therapeutics Q4 Adj. EPS $(0.10) Beats $(0.99) Estimate, Sales $114.109M Beat $12.567M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analys

Earnings Summary: Beam Therapeutics Q4
benzinga.com
Earnings Summary: Beam Therapeutics Q4

Earnings Scheduled For February 24, 2026
benzinga.com
Earnings Scheduled For February 24, 2026

Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
benzinga.com
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts

benzinga.com
Canaccord Genuity Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of

Canaccord Genuity analyst Whitney Ijem initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with

benzinga.com
Bernstein Maintains Outperform on Beam Therapeutics, Raises Price Target to $41

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?
benzinga.com
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?

Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updat

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
benzinga.com
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On

benzinga.com
Reported Earlier, Beam Therapeutics Sets 2026 Strategic Priorities, Aligns With U.S. FDA On Potenti

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 An

benzinga.com
UBS Initiates Coverage On Beam Therapeutics with Neutral Rating, Announces Price Target of $28

UBS analyst Michael Yee initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Neutral rati

Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
benzinga.com
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Movi

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
benzinga.com
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

benzinga.com
Reported Saturday, Beam Therapeutics Highlights Risto-Cel Durable Hemoglobin F Induction >60% And He

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Sh

benzinga.com
Evercore ISI Group Initiates Coverage On Beam Therapeutics with Outperform Rating, Announces Price T

Evercore ISI Group analyst Cory Kasimov initiates coverage on Beam Therapeutics (NASDAQ:BEAM) wit

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
benzinga.com
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, thr

benzinga.com
Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the anal

benzinga.com
Beam Therapeutics To Present Updated Safety, Efficacy Data From BEACON Phase 1/2 Clinical Study Of B

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicine

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday
benzinga.com
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday

benzinga.com
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) wi

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves
benzinga.com
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analyst

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
benzinga.com
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
benzinga.com
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
benzinga.com
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbn

benzinga.com
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Mov

benzinga.com
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher

benzinga.com
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Se

Gainers

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 647 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's session, 201 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  During Tuesday's trading, 188 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday's session, 92 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  During Wednesday's trading, 103 companies set new 52-week lows.

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022